Companies › Bellus Health Inc. - a GSK company
1 active drug program in 1 registered trial: 1 Phase 3; Respiratory; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Camlipixant (BLU-5937) P2X purinoceptor 3 antagonist | P2RX3 | Phase 3 | Cough | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05600777 | Camlipixant (BLU-5937) | Phase 3 | Cough | Respiratory | Mar 2027 |
Kringle Pharma Biotest Areteia Therapeutics PureTech Renovion
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.